BofA lowered the firm’s price target on U.S. Physical Therapy (USPH) to $112 from $115 and keeps a Buy rating on the shares. The company’s 2025 adjusted EBITDA guidance brackets consensus and the firm’s estimates with the implied growth in double digits “impressive given another year of negative Medicare rate update,” says the analyst, who reduced 2025/26 EBITDA forecasts to reflect the guidance.